Provided by Tiger Trade Technology Pte. Ltd.

CytomX Therapeutics

5.43
+0.05501.02%
Volume:672.61K
Turnover:3.59M
Market Cap:919.19M
PE:13.47
High:5.47
Open:5.19
Low:5.17
Close:5.37
52wk High:6.35
52wk Low:0.4000
Shares:169.44M
Float Shares:113.00M
Volume Ratio:0.88
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4026
EPS(LYR):0.3774
ROE:66.76%
ROA:9.78%
PB:8.56
PE(LYR):14.37

Loading ...

CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)

TIPRANKS
·
Nov 07, 2025

Stock Track | CytomX Therapeutics Plunges 5.49% After-Hours on Q3 Earnings Miss and Revenue Shortfall

Stock Track
·
Nov 07, 2025

CytomX Therapeutics Q3 Revenue USD 5.963 Million Vs. IBES Estimate USD 11.6 Million

Reuters
·
Nov 07, 2025

CytomX Therapeutics Q3 EPS $(0.09) Misses $(0.05) Estimate, Sales $5.963M Miss $11.625M Estimate

Benzinga
·
Nov 07, 2025

CytomX Therapeutics reports third quarter 2025 financial results

Reuters
·
Nov 07, 2025

CytomX Therapeutics Inc - Ends Q3 2025 With $143.6 Mln in Cash and Investments, With Expected Cash Runway to Q2 of 2027

THOMSON REUTERS
·
Nov 07, 2025

CytomX Therapeutics Inc expected to post a loss of 5 cents a share - Earnings Preview

Reuters
·
Nov 05, 2025

CytomX Therapeutics Unveils Promising Phase 1 CX-801 Data in Advanced Melanoma at SITC 2025

Reuters
·
Nov 04, 2025

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire
·
Oct 30, 2025

CytomX Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Rachael Lester

Reuters
·
Oct 30, 2025

Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051

TIPRANKS
·
Oct 27, 2025

CytomX Therapeutics management to meet with Oppenheimer

TIPRANKS
·
Oct 22, 2025

CytomX Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
Oct 21, 2025

CytomX Therapeutics (CTMX) Gets a Buy from Barclays

TIPRANKS
·
Oct 21, 2025

CytomX Names Rachael Lester as Chief Business Officer

MT Newswires Live
·
Oct 21, 2025

Press Release: CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

Dow Jones
·
Oct 21, 2025

Oppenheimer positive on CytomX after Merus colon cancer data

TIPRANKS
·
Oct 15, 2025

CytomX Therapeutics Up Nearly 10%, on Track for Highest Close Since May 2024 -- Data Talk

Dow Jones
·
Sep 30, 2025

Why CytomX Therapeutics Stock Was Skyrocketing This Week

Motley Fool
·
Sep 26, 2025

CytomX Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 22, 2025